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rapidly acting, and potent P2Y12
platelet receptor inhibitor, com-
pared with clopidogrel in patients
undergoingpercutaneous coronary
intervention (PCI) for various
clinical indications (1). Cangrelor
was shown at 48 h after PCI
to signiﬁcantly reduce the rate of
ischemic events, a composite end-
point that included stent throm-
bosis (ST). ST was deﬁned in
CHAMPION PHOENIX as theoccurrence of events occurring after the PCI procedure, as
classiﬁed by the Academic Research Consortium (ARC)
deﬁnition (2), as well as intraprocedural ST (IPST), the
development of new or increasing thrombus in or adjacent to an
implanted stent during the PCI procedure. Although previous
reports have linked IPST to future ischemic events (3–5), its
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core laboratory analysis to date.Methods
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621site, procedural anticoagulant (bivalirudin, unfractionated
heparin, low-molecular-weight heparin, or fondaparinux)
and sheath management were per-site routine. Glyco-
protein IIb/IIIa inhibitors were allowed only as rescue
therapy during PCI to treat thrombotic complications.
Study endpoints. The primary efﬁcacy endpoint was the
composite rate of all-cause mortality, MI, ischemia-driven
revascularization (IDR), or ST in the 48 h after randomi-
zation. The key secondary endpoint was the incidence of ST
at 48 hours. ST was deﬁned as the occurrence of IPST or
ARC ST (further classiﬁed as deﬁnite, probable, or possible
ST) (2). IPST was deﬁned as any angiographically new or
worsening thrombus related to stent implantation occurringTable 1 Baseline Clinical Characteristics Accordin
Characteristic
IPS
(n ¼
Age (yrs) 63.0 (
Female 31/89 (
Body mass index (kg/m2) 28.1 (25
Medical history
Diabetes mellitus 26/89 (
Current smoker 33/86 (
Hypertension 69/89 (
Hyperlipidemia 54/78 (
Prior stroke/TIA 4/89 (
Prior MI 19/85 (
Prior PTCA/PCI 15/88 (
Prior CABG 9/88 (
History of CHF 8/88 (
History of peripheral artery disease 11/89 (
Region
United States 24/89 (
Non-U.S. 65/89 (
Patient presentation
NSTE-ACS 33/89 (
Stable angina 32/89 (
STEMI 24/89 (
Baseline cardiac biomarkers
Normal 38/89 (
Abnormal 51/89 (
Periprocedural medications
Aspirin 87/89 (
Unfractionated heparin 67/89 (
Clopidogrel loading dose 600 mg 58/89 (
Clopidogrel loading dose 300 mg 31/89 (
Glycoprotein IIb/IIIa inhibitor 31/89 (
Bivalirudin 18/89 (
Low molecular weight heparin 4/89 (
Fondaparinux 0/89 (
Catheter access site
Femoral 72/89 (
Radial 17/89 (
Brachial 0/89 (
Length of stay (randomization to discharge, h) 45.6 (26.
Values are median (interquartile range) or n/N (%).
CABG ¼ coronary artery bypass grafting; IPST ¼ intra-procedural stent throm
PCI ¼ percutaneous coronary intervention; PTCA ¼ percutaneous translum
infarction.during the PCI procedure, as assessed in frame-by-frame
analysis by a blinded independent core laboratory (Cardio-
vascular Research Foundation, New York, New York) (5).
Thrombus was deﬁned as any discrete, mobile, intraluminal
ﬁlling defect, with deﬁned borders, with or without associ-
ated contrast staining or a total occlusion with convex edges
and staining. Thrombus was described as: 1) occlusive
(TIMI [Thrombolysis In Myocardial Infarction] ﬂow grade
0, occupying the entire lumen); 2) globular (deﬁnite border
on 3 edges); 3) ﬁlling defect (deﬁnite borders on 2 edges); or
4) hazy (irregular contour, smooth convex meniscus or
haziness at the site of the lesion). Thrombus area was traced
to better characterize the thrombotic burden. In cases ofg to the Occurrence of IPST
T
89)
No IPST
(n ¼ 10,850) p Value
55–74) 64.0 (56–72) 0.76
34.8) 3,019/10,850 (27.8) 0.14
.4–31.6) 28.4 (25.6–31.8) 0.43
29.2) 3,028/10,835 (27.9) 0.79
38.4) 3,020/10,589 (28.5) 0.04
77.5) 8,635/10,821 (79.8) 0.60
69.2) 6,647/9606 (69.2) 0.99
4.5) 511/10,815 (4.7) 0.92
22.4) 2,248/10,784 (20.8) 0.73
17.0) 2,586/10,832 (23.9) 0.13
10.2) 1,069/10,839 (9.9) 0.91
9.1) 1,128/10,825 (10.4) 0.68
12.4) 821/10,734 (7.6) 0.10
0.04
27.0) 4,073/10,850 (37.5)
73.0) 6,777/10,850 (62.5)
0.0006
37.1) 2,777/10,850 (25.6)
36.0) 6,106/10,850 (56.3)
27.0) 1,967/10,850 (18.1)
<0.0001
42.7) 6,912/10,841 (63.8)
57.3) 3,929/10,841 (36.2)
97.8) 10,022/10,842 (94.3) 0.16
75.3) 7,459/10,849 (68.8) 0.19
65.2) 8,075/10,850 (74.4) 0.047
34.8) 2,775/10,850 (25.6) 0.047
34.8) 349/10,850 (3.2) <0.0001
20.2) 2,463/10,848 (22.7) 0.58
4.5) 509/10,848 (4.7) 0.93
0) 31/10,849 (0.3) 0.61
0.29
80.9) 7,992/10,850 (73.7)
19.1) 2,835/10,850 (26.1)
0) 23/10,850 (0.2)
2–136.2) 27.0 (23.0–51.1) <0.0001
bosis; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome;
inal coronary angioplasty; STEMI ¼ ST-segment elevation myocardial
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622complete occlusion, the thrombus area was measured after
wire introduction (when possible) and before any device
therapy (thromboaspiration, balloon, or stent). Interobserver
level of agreement for thrombus detection at baseline and
during PCI was 0.95 and 0.8 (kappa statistic), respectively,
indicative of an almost perfect level of agreement (7). The
primary safety endpoint was severe bleeding not related to
coronary artery bypass grafting according to the GUSTO
(Global Use of Strategies to Open Occluded CoronaryTable 2
Baseline Angiographic and Procedural C
Occurrence of IPST
IPST (n ¼
Number of vessels with stenosis >50%
0 0/89 (0.0
1 38/89 (42
2 25/89 (28
3 17/89 (19
>3 9/89 (10
Number of vessels per patient undergoing
PCI during the Index procedure
0 0/89 (0.0
1 70/89 (78
2 14/89 (15
3 4/89 (4.5
>3 1/89 (1.1
Vessels treated
Right coronary artery 29/89 (32
Left anterior descending artery 51/89 (57
Left circumﬂex artery 28/89 (31
Left main 6/89 (6.7
Drug-eluting stent(s) implanted 47/89 (52
Bare metal stent(s) implanted 50/89 (56
Total stent length implanted (mm) 37.0 (23.0–
Time from study drug administration
to start of PCI (min)
4 (2–8
Duration of PCI (min) 37.0 (21
Patients with IVUS-guided PCI 6/89 (6.7
Pre-TIMI ﬂow grade
0 18/89 (20
1 8/89 (9.0
2 13/89 (14
3 50/89 (56
Post-TIMI ﬂow grade
0 6/88 (6.8
1 7/88 (8.0
2 6/88 (6.8
3 69/88 (78
Lesion length 15.9 (11.4–
Thrombus at baseline 38/89 (42
Thrombus area (mm2) 17.7 (10.5–
Tortuosity Moderate or Severe 6/89 (6.7
Calciﬁcation
None/mild 66/89 (74
Moderate 18/89 (20
Severe 5/89 (5.6
Values are n/N (%) or median (interquartile range).
IPST ¼ intra-procedural stent thrombosis; IVUS ¼ intravascular ultrasoun
Myocardial Infarction.Arteries) criteria at 48 h. Detailed deﬁnitions of the primary
and major secondary endpoints have been previously
reported (1). The primary efﬁcacy endpoints occurring
during the ﬁrst 30 days after randomization were adjudicated
by an independent clinical events committee (Duke Clinical
Research Institute, Durham, North Carolina).
Statistical analysis. All of the analyses were performed
with data from the modiﬁed intention-to-treated (mITT)
population, as previously described (1). Continuous variablesharacteristics According to the
89) No IPST (n ¼ 10,850) p Value
) 3/10,832 (0.0) 0.39
.7) 5,255/10,832 (48.5)
.1) 3,245/10,832 (30.0)
.1) 1,691/10,832 (15.6)
.1) 638/10,832 (5.9)
) 98/10,850 (0.9) 0.009
.7) 9,076/10,850 (83.6)
.7) 1,477/10,850 (13.6)
) 188/10,850 (1.7)
) 11/10,850 (0.1)
.6) 3,884/10,850 (35.8) 0.53
.3) 5,368/10,850 (49.5) 0.14
.5) 3,117/10,850 (28.7) 0.57
) 269/10,850 (2.5) 0.011
.8) 6,033/10,850 (55.6) 0.60
.2) 4,601/10,850 (42.4) 0.009
59.0) 23.0 (16.0–36.0) <0.0001
) 4 (2–8) 0.99
–60) 17.0 (10–30) <0.0001
) 605/10,850 (5.6) 0.63
0.005
.2) 1,694/10,727 (15.8)
) 386/10,727 (3.6)
.6) 1,041/10,727 (9.7)
.2) 7,606/10,727 (70.9)
<0.0001
) 87/10,542 (0.8)
) 92/10,542 (0.9)
) 356/10,542 (3.4)
.4) 10,007/10,542 (94.9)
24.3) 13.1 (9.4–19.3) 0.0007
.7) 2,562/10,740 (23.9) <0.0001
28.6) 13.2 (8.1–21.4) 0.28
) 319/10,718 (3.0) 0.04
0.99
.2) 7,948/10,657 (74.6)
.2) 2,133/10,657 (20.0)
) 576/10,657 (5.4)
d; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In
Table 3 Independent Predictors of IPST
Variable
Adjusted Odds Ratio
(95% CI) p Value
STEMI (vs. SA) 1.87 (1.04–3.36) 0.04
NSTE-ACS (vs. SA) 2.07 (1.26–3.40) 0.004
Thrombus at baseline 1.79 (1.12–2.84) 0.01
Total stent length
(per 1-mm increase)
1.03 (1.02–1.03) <0.0001
Cangrelor at randomization
(vs. clopidogrel)
0.65 (0.42–1.00) 0.048
*Candidate variables included in the model: current smoker, diagnosis at presentation (stable
angina vs. NSTE-ACS vs. STEMI), number of PCI vessels, DES versus BMS used, total stent length,
TIMI ﬂow at baseline (3 vs. 0-1-2), presence of thrombus at baseline, U.S. versus non-U.S. site,
cangrelor infusion.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); SA ¼ stable angina; other abbreviations
as in Tables 1 and 2.
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623are summarized as medians and quartiles or as mean  SD,
as appropriate, and were compared using the Student t test
or Mann-Whitney rank sum test accordingly. Categorical
variables are presented as rate (%) and were compared by the
chi-square or Fisher exact test. Time-to-event curves were
constructed using Kaplan-Meier methodology and com-
pared with the log-rank test. Logistic regression was per-
formed to identify independent predictors of IPST. The
multivariable model was built by selecting variables of clin-
ical interest and/or satisfying the entry criterion of a < 0.05
in the univariate analysis. The number of variables included
in the model was chosen to avoid overﬁtting. The ﬁnal
model was derived with a stepwise regression procedure
with entry/stay a criteria of 0.10. To assess the association
between the occurrence of IPST and subsequent all-cause
death, MI, ARC ST, ARC deﬁnite ST, and IDR, logistic
regression was used to derive a propensity score for IPST,
which was then included in a logistic regression modelTable 4 Relationship Between IPST and Subsequent 48-Hour and 30
Time Point/
Endpoint
IPST
(n ¼ 89)
No IPST
(n ¼ 10,850) OR
48 h
Death/MI/IDR/ARC-ST 26 (29.2) 490 (4.5) 8.73 (
Death 5 (5.6) 31 (0.3) 20.77 (
ARC deﬁnite ST 3 (3.4) 31 (0.3) 12.17 (
IDR 4 (4.5) 62 (0.6) 8.19 (
MI 23 (25.8) 439 (4.0) 8.26 (
30 days*
Death/MI/IDR/ARC-ST 28 (31.5) 617 (5.7) 7.60 (
Death 9 (10.1) 106 (1.0) 11.38 (
ARC ST 5 (5.6) 86 (0.8) 7.44 (
ARC deﬁnite ST 4 (4.5) 61 (0.6) 8.31 (
IDR 5 (5.6) 117 (1.1) 5.45 (
MI 24 (27.0) 473 (4.4) 8.08 (
Values are n (%). *30-day efﬁcacy data were unavailable in 20 patients in the no-IPST group (n ¼ 10,83
biomarker, previous MI (stable angina vs. NSTE-ACS vs. STEMI), previous PCI, previous CABG, peripheral ar
aspirin dose, number of treated vessels, clopidogrel loading received, clopidogrel loading dose (300 vs
modeling.
AOR ¼ adjusted odds ratio; ARC ¼ Academic Research Consortium; IDR ¼ ischemia-driven revascula(along with IPST) for 48-h and 30-day outcomes. Inter-
action between the occurrence of IPST and different
subgroups on major adverse events was tested using the
Breslow-Day method. No adjustment was made for mul-
tiple comparisons. All statistical analyses were performed
with SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).Results
Patients and baseline characteristics. Detailed angio-
graphic core laboratory analysis was completed in 10,939 of
10,942 randomized patients (99.9%) in the mITT cohort.
Among those, IPST occurred in 89 patients (0.8%),
including 35 of 5,470 (0.6%) and 54 of 5,469 (1.0%) patients
in the cangrelor and clopidogrel arms, respectively (odds ratio
[OR]: 0.65; 95% conﬁdence interval [CI: 0.42 to 0.99;
p ¼ 0.04). IPST occurred in 32 of 6,138 patients (0.5%)
presenting with stable angina, 33 of 2,810 patients (1.2%)
presenting with NSTE-ACS, and 24 of 1,991 patients
(1.2%) presenting with STEMI (p ¼ 0.0006). Among IPST
patients, 48 of 89 (53.9%) had new evidence of thrombus,
and 41 of 89 (46.1%) had worsening or growing thrombus.
Baseline clinical, angiographic, and procedural charac-
teristics of patients with and without IPST are shown in
Tables 1 and 2. Patients with versus without IPST were
more frequently current smokers, treated outside of the
United States, presented with NSTE-ACS or STEMI
rather than stable angina, had elevated baseline cardiac
biomarkers (troponin and/or creatine kinase-MB), and
received a loading dose of 300 mg rather 600 mg of clopi-
dogrel. Patients with IPST more frequently had baseline and
ﬁnal TIMI ﬂow grade <3, had thrombotic lesions, under-
went multivessel PCI, were treated with bare-metal stents-Day Adverse Ischemic Events
Unadjusted Adjusted
(95% CI) p Value AOR (95% CI) p Value
5.48–13.90) <0.0001 11.85 (7.08–19.84) <0.0001
7.89–54.73) <0.0001 20.82 (7.34–59.02) <0.0001
3.65–40.58) <0.0001 12.15 (3.46–42.68) <0.0001
2.91–23.01) <0.0001 10.32 (3.50–30.37) <0.0001
5.09–13.41) <0.0001 12.00 (6.97–20.64) <0.0001
4.82–11.97) <0.0001 9.65 (5.86–15.89) <0.0001
5.57–23.27) <0.0001 12.25 (5.76–26.05) <0.0001
2.95–18.79) <0.0001 7.56 (2.91–19.65) <0.0001
2.95–23.36) <0.0001 8.17 (2.81–23.77) <0.0001
2.17–13.68) <0.0001 6.36 (2.46–16.40) <0.0001
5.02–13.03) <0.0001 11.34 (6.66–19.30) <0.0001
0). Propensity score based upon age, sex, smoking status, U.S. versus non-US region, race, weight,
tery disease, patient presentation, worst pre-procedure TIMI score, stent type, bifurcation treatment,
. 600 mg), cangrelor infusion duration, bivalirudin received. Missing data were excluded from the
rization; OR ¼ odd ratio; ST ¼ stent thrombosis; other abbreviations as in Tables 1 and 2.
Figure 1 Time-to-Event Through 30 Days in Patients With and Without IPST
(A) 30-Day mortality. (B) 30-Day mortality with 48-h landmark analysis. (C) 30-Day Academic Research Consortium (ARC) (deﬁnite or probable) stent thrombosis.
(D) 30-day ARC stent thrombosis with 48-h landmark analysis. HR ¼ hazard ratio; IPST ¼ intraprocedural stent thrombosis. Continued on the next page
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624rather than drug-eluting stents and longer stents, and had
a lengthier PCI procedure. Of note, 78.4% of IPST patients
had TIMI ﬂow grade 3 after the procedure, suggesting
resolution of the thrombotic event in most patients. IPST
was also associated with a doubling of the duration of
hospitalization (Table 1).
As shown in Table 3, by multivariate analysis, NSTE-
ACS and STEMI at presentation, angiographic thrombus
prior to PCI, and total stent length were independent
predictors of IPST. The use of cangrelor at randomization
(compared to clopidogrel) was independently associated with
freedom from IPST during PCI.
Clinical outcomes. IPST was associated with a marked
increase in mortality, MI, IDR, and ARC ST at 48 h and at
30 days (Table 4, Fig. 1). After controlling for potential
confounders, IPST remained a strong predictor of all
adverse ischemic events, including mortality and ARC ST
(deﬁnite and deﬁnite or probable) outside the catheterization
laboratory, at both time periods. The independent associa-
tion between IPST and these adverse ischemic eventsremained independent, even among patients in whom IPST
treatment restored ﬁnal angiographic TIMI ﬂow grade 3
(Table 5). The impact of IPST on 30-day mortality was
consistent among speciﬁed subgroups (Fig. 2). The associ-
ation between the occurrence of IPST and ARC deﬁnite ST
(at 48 h and 30 days) and subsequent mortality is shown in
Figure 3. Among patients experiencing deﬁnite ST by 48 h
and 30 days, 3 of 34 (8.8%) and 4 of 65 (6.2%) patients,
respectively, had an earlier IPST. Similarly, 84 of 89 patients
with IPST did not experience ARC ST at 30 days, and 86 of
91 ARC ST did not have IPST, indicating little overlap
between both outcomes. IPST was also associated with an
increase in bleeding events (moderate and mild GUSTO
bleeding, minor TIMI bleeding, Bleeding Academic
Research Consortium [BARC] 3a, and ACUITY [Acute
Catheterization and Urgent Intervention Triage Strategy]
major bleeding [excluding hematoma 5 cm]) at 48 h
(Table 6).
Use of cangrelor resulted in a signiﬁcant reduction in the
rate of IPST compared with clopidogrel in the entire study
Figure 1 Continued
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625population and separately in the patient cohorts presenting
with stable angina, NSTE-ACS, and STEMI (Fig. 4).
Discussion
The current analysis from 10,939 patients enrolled in
the multinational, prospective, double-blind randomized
CHAMPION PHOENIX trial is the largest study to
speciﬁcally evaluate the incidence, predictors, and impact of
IPST on the early prognosis of patients undergoing elective,
urgent, and emergent PCI. The main results of the present
study are as follows: 1) IPST occurred in approximately 1%
of patients undergoing PCI; 2) NSTE-ACS or STEMI at
presentation, the presence of angiographic thrombus, and
the total stent length implanted were independently associ-
ated with the occurrence of IPST, and cangrelor use inde-
pendently associated with freedom of IPST; 3) IPST was
associated with a signiﬁcant increase in mortality, MI, IDR,
and ARC deﬁnite or probable ST at 48 h and at 30 days; and
4) treatment with cangrelor compared to clopidogrel at the
time of the PCI procedure signiﬁcantly decreased the
occurrence of IPST and adverse events through 30 days.IPST was an infrequent event during PCI, occurring in
0.8% of PCI patients in the CHAMPION PHOENIX
trial. Similar results have been reported by previous groups,
with an incidence varying from 0.5% to 0.7% (3–5). From
a pooled analysis of the ACUITY (8) and HORIZONS-
AMI (Harmonizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction) trials (9), IPST
occurred in 47 (0.7%) of the 6,591 analyzed patients, with
a higher incidence in STEMI compared to NSTE-ACS
(1.2% vs. 0.3%, respectively) (5). The rate of IPST in
CHAMPION PHOENIX was similar to that in
HORIZONS-AMI (1.2%), although IPST occurred more
frequently in NSTE-ACS patients in the present study
than in ACUITY (1.2% vs. 0.3%, respectively) (5). As the
angiographic core laboratory and methodology to assess
IPST were the same in both studies, this difference is likely
explained by underlying differences in the patient pop-
ulations and adjunct pharmacology between the 2 studies.
In the present study, IPST was notably less common in
patients with stable coronary artery disease (incidence 0.5%),
consistent with the lower rate of out-of-laboratory ST in
these patients compared to NSTE-ACS and STEMI.
Table 5
Relationship Between IPST and Subsequent 48-H and 30-Day Adverse Ischemic Events in Patients With
Post–PCI TIMI Flow Grade 3
Time Point/
Endpoint
IPST
(n ¼ 69)
No IPST
(n ¼ 10,007)
Unadjusted Adjusted
OR (95% CI) p Value AOR (95% CI) p Value
48 h
Death/MI/IDR/ARC-ST 18 (26.1) 429 (4.3) 7.88 (4.56–13.60) <0.0001 10.24 (5.64–18.60) <0.0001
Death 2 (2.9) 20 (0.2) 14.91 (3.42–65.04) <0.0001 15.95 (3.38–75.35) 0.0005
ARC Deﬁnite ST 3 (4.3) 23 (0.2) 19.73 (5.78–67.32) <0.0001 20.58 (5.64–75.08) <0.0001
IDR 4 (5.8) 43 (0.4) 14.26 (4.97–40.88) <0.0001 15.50 (5.15–46.62) <0.0001
MI 16 (23.2) 397 (4.0) 7.31 (4.14–12.90) <0.0001 9.74 (5.21–18.19) <0.0001
30 days*
Death/MI/IDR/ARC-ST 20 (29.0) 535 (5.4) 7.21 (4.26–12.22) <0.0001 8.85 (5.00–15.65) <0.0001
Death 4 (5.8) 79 (0.8) 7.72 (2.75–21.70) <0.0001 8.55 (2.94–24.84) <0.0001
ARC ST 5 (7.2) 67 (0.7) 11.57 (4.51–29.66) <0.0001 12.28 (4.64–32.55) <0.0001
ARC Deﬁnite ST 4 (5.8) 48 (0.5) 12.74 (4.47–36.37) <0.0001 12.94 (4.36–38.39) <0.0001
IDR 5 (7.2) 91 (0.9) 8.50 (3.34–21.61) <0.0001 8.87 (3.39–23.17) <0.0001
MI 17 (24.6) 424 (4.2) 7.38 (4.23–12.86) <0.0001 9.66 (5.25–17.76) <0.0001
Values are n (%). *Thirty-day efﬁcacy data were unavailable in 18 patients in the no-IPST group. Propensity score based upon age, sex, smoking status, U.S. versus non-U.S. region, race, weight, biomarker,
previous MI (stable angina vs. NSTE-ACS vs. STEMI), previous PCI, previous CABG, peripheral artery disease, patient presentation, worst pre-procedure TIMI score, stent type, bifurcation treatment, aspirin
dose, number of treated vessels, clopidogrel loading dose (300 vs. 600 mg), infusion duration, bivalirudin received. Missing data were excluded from the modeling.
Abbreviations as in Tables 1, 2, and 4.
Généreux et al. JACC Vol. 63, No. 7, 2014
Intraprocedural Stent Thrombosis as an Endpoint February 25, 2014:619–29
626The current study demonstrates a strong independent
relationship between IPST and short-term mortality. After
propensity-score–adjusted multivariable analysis, IPST was
associated with increases of >20- and >12-fold in 48-h and
30-day mortality, respectively. Brener et al. (5) reported
similar results in ACS patients, with IPST associated with
a 10-fold increase in 30-day mortality. IPST was also
a strong independent predictor of MI and IDR. Of note,Figure 2 Subgroup Analysis on the Impact of IPST on 30-Day Mortal
The negative impact of intraprocedural stent thrombosis (IPST) on 30-day mortality was co
elevation acute coronary syndrome; OR ¼ odds ratio; PCI ¼ percutaneous coronary intervwhile 5.6% of patients with IPST died within 48 h, an
additional w5% died between 48 h and 30 days. This
ﬁnding underscores the importance of preventing IPST, as
well as close monitoring and optimal treatments should
IPST occur. Additionally, in approximately one-third of the
cases, IPST was associated with use of bailout glycoprotein
IIb/IIIa inhibitors, with attendant bleeding hazards and
ﬁnancial implications. Furthermore, prevention of IPSTity
nsistent among speciﬁed subgroups. LM ¼ left main; NSTE-ACS ¼ non–ST-segment
ention; SA ¼ stable angina; STEMI ¼ ST-segment elevation myocardial infarction.
Figure 3 Impact of IPST and ARC Stent Thrombosis on Mortality
(A) 48-h mortality. (B) 30-day mortality. Abbreviations as in Figures 1 and 2.
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627may reduce costs because IPST was associated with a
doubling in the length of stay.
In addition, IPST was independently predictive of
ARC-ST and ARC deﬁnite ST outside the catheterization
laboratory. Indeed, IPST was associated with increases of
approximately 12-fold and 8-fold in (angiographically
conﬁrmed) newly symptomatic ARC deﬁnite ST at 48 h and
30 days, respectively. Moreover, while IPST was a relatively
rare intraprocedural event, in the CHAMPION PHOENIX
trial, its incidence (0.8%) was higher than that of ARC deﬁnite
ST at 48 h (0.3%) and 30 days (0.6%), and was associated with
a similar detrimental impact on short-term prognosis (1).
Bleeding rates were also higher in patients experiencing IPST,
likely due to the more frequent use of aggressive bailout
antithrombotic strategies (such as glycoprotein IIb/IIIa
inhibitors) to treat IPST. Moreover, the deleterious impact of
IPST persisted even in patients in whom TIMI ﬂow grade 3
was present at the end of the PCI procedure. The present study
thus clearly establishes the prognostic utility of IPST, justifying
its assessment in future clinical trials in which intraprocedural
antithrombotic efﬁcacy is being evaluated. These ﬁndings also
suggest that future iterations of ST classiﬁcations should
incorporate IPST as a discrete category.Independent predictors of IPST in the current report were
NSTE-ACS and STEMI at presentation, angiographic
thrombus at baseline, and total stent length used during the
index PCI. Previous studies have similarly identiﬁed ACS
and thrombus to be predictors of out-of-laboratory ST
(10–14). The fact that stent length was predictive of IPST is
also consistent with prior reports of post-PCI ST (12,14).
The use of cangrelor was also identiﬁed as an independent
predictor of freedom from IPST. Because none of the novel
oral P2Y12 receptor blockers (prasugrel, ticagrelor) showed
efﬁcacy in reducing acute ST per se (15–17), this ﬁnding may
have major implications when selecting the most potent
antithrombotic treatment during PCI.
Importantly, use of the potent, rapid-acting ADP
receptor antagonist cangrelor compared with clopidogrel
(begun at the time of PCI) resulted in a 35% reduction in
the rate of IPST, with efﬁcacy in this regard evident in
patients with stable angina, NSTE-ACS, and STEMI.
Cangrelor may be particularly advantageous to prevent IPST
in patients in whom potent oral agents have not been started
prior to PCI or in situations in which their absorption is
delayed, such as in STEMI (18,19). Thus, the present and
prior ﬁndings emphasize the interplay between the patient/
Table 6 Association Between IPST and Subsequent 48-Hour Bleeding Events
Endpoint
IPST
(n ¼ 89)
No IPST
(n ¼ 10,850) OR (95% CI) p Value
GUSTO bleeding
Non–CABG-related 17 (19.1) 1,424 (13.1) 1.56 (0.92–2.66) 0.10
Any 6 (6.7) 277 (2.6) 2.76 (1.19–6.37) 0.01
Severe/life threatening 0 (0) 15 (0.1) – 0.73
Moderate 1 (1.1) 34 (0.3) 3.61 (0.49–26.70) 0.18
Mild 5 (5.6) 231 (2.1) 2.74 (1.10–6.81) 0.02
TIMI bleeding
Any 1 (1.1) 21 (0.2) 5.86 (0.78–44.04) 0.051
Major 0 (0) 10 (0.1) – 0.77
Minor 1 (1.1) 11 (0.1) 11.20 (1.43–87.66) 0.004
BARC bleeding
Any 17 (19.1) 1,424 (13.1) 1.56 (0.92–2.66) 0.10
BARC type 3 1 (1.1) 34 (0.3) 3.61 (0.49–26.70) 0.18
BARC type 3a 1 (1.1) 14 (0.1) 8.80 (1.14–67.61) 0.01
BARC type 3b 0 (0) 17 (0.2) – 0.71
BARC type 3c 0 (0) 3 (0) – 0.88
ACUITY major without hematoma 5 cm 2 (2.2) 52 (0.5) 4.77 (1.14–19.91) 0.02
Values are n (%).
ACUITY ¼ Acute Catheterization and Urgent Intervention Triage Strategy; BARC ¼ Bleeding Academic Research Consortium; GUSTO ¼ Global Use
of Strategies to Open Occluded Arteries; other abbreviations as in Tables 1 and 4.
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628lesion thrombotic environment, stent platform, and antith-
rombotic therapy on the occurrence of intraprocedural and
early ST. Optimization of each of these components is
crucial if PCI outcomes are to be improved.
Study limitations. Although rigorous angiographic assess-
ment was performed by an experienced, independent,
angiographic core laboratory, IPST could be diagnosed only
if appropriate angiographic documentation was provided by
each site investigator. Thus, brief occurrences of abruptFigure 4
Incidence of IPST, Stratiﬁed by Initial Presentation
and Antiplatelet Therapy Strategy
Cangrelor was associated with a signiﬁcant reduction in the rate of IPST compared
with clopidogrel. No interaction was demonstrated among clinical presentation
modes (stable angina, NSTE-ACS, and STEMI), suggesting a similar beneﬁcial
effect of cangrelor among these groups. Abbreviations as in Figures 1 and 2.vessel closure or treatment of thrombus that were not
recorded would have escaped detection in this analysis.
Coronary angiography has been shown to have great speci-
ﬁcity for thrombus detection but low sensitivity compared
with angioscopy, resulting in potential underestimation of
thrombus burden at the lesion level (20). Although its
clinical role still remains to be established, the use of novel
intracoronary imaging techniques, such as optical coherence
tomography, could have been useful to better characterize
and quantify new or worsening intraprocedural thrombus
compared with the conventional angiographic evaluation.
The absolute number of IPST events prevented was 0.4%,
meaning that many patients would need to be treated to
prevent 1 event. However, IPST was 3-fold more common
than ARC deﬁnite ST and has similar prognostic implica-
tions, warranting efforts to prevent its occurrence. IPST
had a low positive predictive value for ARC ST after PCI,
suggesting that different mechanisms may be responsible
for IPST and later ST. Finally, although IPST was strongly
related to subsequent adverse ischemic events in a multivar-
iable model after propensity adjustment for those factors
related to IPST (and other variables), the presence of
residual confounding elements cannot be excluded.Conclusions
In the large-scale CHAMPION PHOENIX trial, IPST
was a relatively infrequent event, occurring in <1% of
patients undergoing PCI, but was strongly associated with
subsequent ischemic events, including out-of-laboratory
ST, MI, and death. The reduction in IPST with cangrelor
in CHAMPION PHOENIX contributed to this agent’s
effectiveness in reducing the rates of ARC-deﬁned stent
JACC Vol. 63, No. 7, 2014 Généreux et al.
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629thrombosis and MI. These data provide strong evidence for
a signiﬁcant association between IPST and adverse short-
term clinical outcomes after PCI and support the inclusion
of IPST as an important endpoint in future pharmacological
and device trials.
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